dc.contributor.author |
Ahmadi P. |
|
dc.contributor.author |
Muguruma K. |
|
dc.contributor.author |
Chang T.C. |
|
dc.contributor.author |
Tamura S. |
|
dc.contributor.author |
Tsubokura K. |
|
dc.contributor.author |
Egawa Y. |
|
dc.contributor.author |
Suzuki T. |
|
dc.contributor.author |
Dohmae N. |
|
dc.contributor.author |
Nakao Y. |
|
dc.contributor.author |
Tanaka K. |
|
dc.date.accessioned |
2022-02-09T20:46:43Z |
|
dc.date.available |
2022-02-09T20:46:43Z |
|
dc.date.issued |
2021 |
|
dc.identifier.issn |
2041-6520 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/170218 |
|
dc.description.abstract |
Selective cell tagging (SeCT) therapy is a strategy for labeling a targeted cell with certain chemical moietiesviaa catalytic chemical transformation in order to elicit a therapeutic effect. Herein, we report a cancer therapy based on targeted cell surface tagging with proapoptotic peptides (Ac-GGKLFG-X; X = reactive group) that induce apoptosis when attached to the cell surface. Using either Au-catalyzed amidation or Ru-catalyzed alkylation, these proapoptotic peptides showed excellent therapeutic effects bothin vitroandin vivo. In particular, co-treatment with proapoptotic peptide and the carrier-Ru complex significantly and synergistically inhibited tumor growth and prolonged survival rate of tumor-bearing mice after only a single injection. This is the first report of Ru catalyst applicationin vivo, and this approach could be used in SeCT for cancer therapy. |
|
dc.relation.ispartofseries |
Chemical Science |
|
dc.title |
In vivometal-catalyzed SeCT therapy by a proapoptotic peptide |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
37 |
|
dc.relation.ispartofseries-volume |
12 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
12266 |
|
dc.source.id |
SCOPUS20416520-2021-12-37-SID85116416695 |
|